Active substances
Amlodipine + Indapamide
- SFDA 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| NATRIXAM 1.5 MG/10 MG MR TABLET | 1.5 , 10 mg | modified-release tablet · Oral use | 30 Blister | SAR 38.00 | NCE · Prescription | LES LABORATOIRES SERVIER | Withdrawn by MAH · Not Marketed |
| NATRIXAM 1.5 MG/5 MG MR TABLET | 1.5 , 5 mg | modified-release tablet · Oral use | 30 Blister | SAR 38.00 | NCE · Prescription | LES LABORATOIRES SERVIER | Withdrawn by MAH · Not Marketed |
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.